DE69813542T2 - Arzneizubereitung enthaltend eine trizyklische verbindung mit erhöter stabilität, absorbierbarkeit und niedriger reizungsneigung - Google Patents

Arzneizubereitung enthaltend eine trizyklische verbindung mit erhöter stabilität, absorbierbarkeit und niedriger reizungsneigung

Info

Publication number
DE69813542T2
DE69813542T2 DE69813542T DE69813542T DE69813542T2 DE 69813542 T2 DE69813542 T2 DE 69813542T2 DE 69813542 T DE69813542 T DE 69813542T DE 69813542 T DE69813542 T DE 69813542T DE 69813542 T2 DE69813542 T2 DE 69813542T2
Authority
DE
Germany
Prior art keywords
absorbability
tricyclic
connection
preparation containing
increased stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69813542T
Other languages
English (en)
Other versions
DE69813542D1 (de
Inventor
Masayuki Yamanaka
Fumio Shimojo
Satoshi Ueda
Toshihiko Toyoda
Rinta Ibuki
Norio Ohnishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69813542D1 publication Critical patent/DE69813542D1/de
Publication of DE69813542T2 publication Critical patent/DE69813542T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
DE69813542T 1997-02-20 1998-02-18 Arzneizubereitung enthaltend eine trizyklische verbindung mit erhöter stabilität, absorbierbarkeit und niedriger reizungsneigung Expired - Lifetime DE69813542T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3617297 1997-02-20
JP25635797 1997-09-22
PCT/JP1998/000665 WO1998036747A1 (en) 1997-02-20 1998-02-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE69813542D1 DE69813542D1 (de) 2003-05-22
DE69813542T2 true DE69813542T2 (de) 2003-11-20

Family

ID=26375217

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813542T Expired - Lifetime DE69813542T2 (de) 1997-02-20 1998-02-18 Arzneizubereitung enthaltend eine trizyklische verbindung mit erhöter stabilität, absorbierbarkeit und niedriger reizungsneigung

Country Status (21)

Country Link
US (1) US6387918B1 (de)
EP (1) EP0977565B1 (de)
JP (1) JP3396888B2 (de)
KR (1) KR100490357B1 (de)
CN (1) CN1178656C (de)
AR (1) AR011846A1 (de)
AT (1) ATE237325T1 (de)
AU (1) AU727337B2 (de)
BR (1) BR9807234B1 (de)
CA (1) CA2282345C (de)
DE (1) DE69813542T2 (de)
DK (1) DK0977565T3 (de)
EA (1) EA003580B1 (de)
ES (1) ES2193515T3 (de)
HK (1) HK1027957A1 (de)
HU (1) HU226163B1 (de)
IL (1) IL131298A (de)
NO (1) NO325103B1 (de)
PT (1) PT977565E (de)
TW (1) TW450810B (de)
WO (1) WO1998036747A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363275T1 (de) * 1998-04-27 2007-06-15 Astellas Pharma Inc Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
IL161786A0 (en) 2001-11-29 2005-11-20 3M Innovative Properties Co Pharmaceutical formulations comprising an immune
CA2498191C (en) 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
PL1663216T3 (pl) 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
CN1859909B (zh) 2003-08-29 2011-04-06 生命周期药物公司 含有他克莫司的固态分散体
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1848431B1 (de) * 2005-02-09 2016-02-03 Santen Pharmaceutical Co., Ltd. Flüssige formulierungen zur behandlung von erkrankungen oder leiden
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US7672006B2 (en) * 2006-02-22 2010-03-02 Xerox Corporation Multi-marking engine printing platform
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
AU2007238896A1 (en) * 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. CGRP antagonist salt
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
DK2167033T3 (en) 2007-05-30 2017-08-14 Veloxis Pharmaceuticals As Once daily oral dosage form comprising tacrolism
EP2345414B1 (de) * 2008-10-08 2014-06-25 Takata Seiyaku Co., Ltd. Tacrolimus-zusammensetzung zur äusseren anwendung
WO2011100975A2 (en) 2010-02-17 2011-08-25 Lifecycle Pharma A/S Stabilized tacrolimus composition
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN103974700B (zh) * 2011-12-07 2015-12-09 久光制药株式会社 贴附剂
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
EP4066822A1 (de) 2015-08-19 2022-10-05 Vivus, Inc. Pharmazeutische formulierungen
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
JP2023528616A (ja) 2020-06-01 2023-07-05 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0406791T3 (da) * 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
DK0474126T3 (de) 1990-09-04 1997-04-07 Fujisawa Pharmaceutical Co
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
JPH06183970A (ja) 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
ATE214593T1 (de) * 1994-10-26 2002-04-15 Novartis Erfind Verwalt Gmbh Verwendung eines ungesättigten fettalkohols

Also Published As

Publication number Publication date
BR9807234A (pt) 2000-04-25
IL131298A (en) 2004-06-20
CN1178656C (zh) 2004-12-08
KR100490357B1 (ko) 2005-05-17
EP0977565A1 (de) 2000-02-09
ATE237325T1 (de) 2003-05-15
EA003580B1 (ru) 2003-06-26
TW450810B (en) 2001-08-21
NO325103B1 (no) 2008-02-04
NO994003D0 (no) 1999-08-19
NO994003L (no) 1999-10-19
DK0977565T3 (da) 2003-08-04
EP0977565B1 (de) 2003-04-16
CA2282345C (en) 2008-10-21
AU727337B2 (en) 2000-12-07
IL131298A0 (en) 2001-01-28
US6387918B1 (en) 2002-05-14
PT977565E (pt) 2004-01-30
AR011846A1 (es) 2000-09-13
ES2193515T3 (es) 2003-11-01
EA199900749A1 (ru) 2000-04-24
HUP0000979A3 (en) 2002-10-28
US20020032212A1 (en) 2002-03-14
HUP0000979A1 (hu) 2000-10-28
BR9807234B1 (pt) 2013-11-05
HK1027957A1 (en) 2001-02-02
CN1252721A (zh) 2000-05-10
KR20000070824A (ko) 2000-11-25
AU6228998A (en) 1998-09-09
JP2000513739A (ja) 2000-10-17
WO1998036747A1 (en) 1998-08-27
JP3396888B2 (ja) 2003-04-14
CA2282345A1 (en) 1998-08-27
DE69813542D1 (de) 2003-05-22
HU226163B1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
DE69813542D1 (de) Arzneizubereitung enthaltend eine trizyklische verbindung mit erhöter stabilität, absorbierbarkeit und niedriger reizungsneigung
NO953874D0 (no) Farmasöytisk preparat inneholdende lipofile legemidler
FI943570A (fi) 1-bentseenisulfonyyli-1,3-dihydroindol-2-onijohdannaisia, niiden valmistus ja niitä sisältäviä lääkeaineita
DE69011059T3 (de) Heterozyklische Acylaminothiazolderivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen.
DE69833464D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
HUP0100059A2 (hu) Új piridazinszármazékok és a vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
EE200200160A (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
IS3878A (is) Imidazodiazepines efnasambönd, framleiðsla þeirraog notkun sem lyfja
HU9502066D0 (en) Pyrrolidine and thiazolidine derivatives, their preparation and drugs containing same
AU3053199A (en) Fused thiophene derivatives and drugs containing the same as the active ingredient
ATE237320T1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
HUP9802807A3 (en) 1,3,8-triazo-spiro[4,5]decan-4-on derivatives, their use, production thereof and medicaments containing the same
AU2557892A (en) New beta -carbolin derivatives, their preparation and their use in drugs
HUP0401318A3 (en) Combined preparations containing 2,3,4,5-tetrahydro-benzo[b]thiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HUP0101131A2 (hu) Gyulladásgátló hatású dihidrobenzopirán-származékok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
DE69722433D1 (de) Pharmazeutische zubereitungen, welche zidovudin und lamivudine enthalten
ZA894422B (en) Pyrrole derivatives,their preparation and their use as pharmaceutical active compounds
EE04347B1 (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, neid sisaldav ravim ja farmatseutiline kompositsioon
DE69907735D1 (de) Melatoninderivate und diese enthaltende pharmazeutische zubereitung
EP0721784A4 (de) Arzneimittelzubereitung mit kontrollierter freisetzung
DE69813624D1 (de) Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
HUP0004661A3 (en) Polyhydroxybutylpyrazines, their preparation and medicines containing them

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP